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Background: DSM-V criteria for insomnia disorder are met by 6 to 10 % of the adult population. Insomnia has
severe consequences for health and society. One of the most common treatments provided by primary caregivers
is pharmacological treatment, which is far from optimal and has not been recommended since a 2005 consensus
report of the National Institutes of Health. The recommended treatment is Cognitive Behavioral Therapy for Insomnia.
Effectiveness, however, is still limited. Only a few studies have evaluated the effectiveness of chronobiological
treatments, including the timed application of bright light, physical activity and body warming. Another opportunity
for optimization of treatment is based on the idea that the people suffering from insomnia most likely represent a
heterogeneous mix of subtypes, with different underlying causes and expected treatment responses.
The present study aims to evaluate the possibility for optimizing insomnia treatment along the principles of
personalized and stratified medicine. It evaluates the following:
1. The relative effectiveness of internet-supported cognitive behavioral therapy, bright light, physical activity and
body warming;
2. Whether the effectiveness of internet-supported cognitive behavioral therapy for insomnia can be augmented
by simultaneous or prior application of bright light, physical activity and body warming; and
3. Whether the effectiveness of the interventions and their combination are moderated by the insomnia subtype.
Methods/Design: In a repeated measures, placebo-controlled, randomized clinical trial that included 160 people
diagnosed with insomnia disorder, we are evaluating the relative effectiveness of 4 intervention weeks. Primary
outcome is subjective sleep efficiency, quantified using a sleep diary. Secondary outcomes include other complaints of
sleep and daytime functioning, health-related cost estimates and actigraphic objective sleep estimates. Compliance will
be monitored both subjectively and objectively using activity, light and temperature sensors. Insomnia subtypes will
be assessed using questionnaires. Mixed effect models will be used to evaluate intervention effects and moderation by
insomnia subtype ratings.
Discussion: The current study addresses multiple opportunities to optimize and personalize treatment of insomnia disorder.
Trial registration: Netherlands National Trial Register NTR4010, 4 June 2013.
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Dissatisfaction with sleep is reported by about 25 % of
the adult Western population [1]. The prevalence is even
higher in older people and twice as high in women as in
men [2, 3]. When complaints about difficulties falling
asleep, maintaining sleep, early morning awakenings or
nonrestorative sleep are accompanied by physical or cog-
nitive daytime complaints, and last for at least 3 months,
occurring at least three times a week, without being
secondary to environmental factors or comorbidities that
prohibit sleep, a person suffers from insomnia disorder,
according to the DSM-V [4]. These criteria are met by 6
to 10 % of adults [2]. Daytime complaints of people with
insomnia concern cognitive functioning [5], depressed
mood [6] and fatigue [6]. Additionally, people reporting
insomnia or low sleep quality have higher risks of depres-
sion [7], metabolic diseases and cardiovascular problems
[8]. These daytime consequences and comorbidities lead
to a reduction in work productivity, to increased sick
leave and healthcare consumption and consequently to
high economic costs. In summary, insomnia has severe
consequences for health and society [9], underscoring the
importance of optimizing interventions to promote bet-
ter sleep. To do so, the regulation of sleep needs to be
considered.
Circadian rhythm and sleep
Virtually all behavioral and physiological processes show
a 24-h rhythm even in the absence of environmental
time cues. This circadian (from circa = about, and dies =
day) rhythm is, for example, present in sleep and wake-
fulness, hormone secretion, alertness, body temperature,
metabolism, perception and cognition. Endogenous clock
mechanisms that promote the expression of 24-h rhythms
are located in all human cells [10] and are synchronized
by the central clock of the brain, the hypothalamic sup-
rachiasmatic nuclei (SCN). The SCN is considered the
major clock because only SCN tissue is able to maintain a
circadian rhythm in the absence of external input [10].
Under normal circumstances, several exogenous cues, or
zeitgebers, entrain the SCN. Light is the strongest zeit-
geber [11]. The retinohypothalamic tract (RHT) is one of
the three major input pathways of the SCN, providing it
with information from photoreceptor cells in the retina.
Secondary zeitgebers include, for example, the tem-
perature of the environment, body core and skin; metab-
olism; and the rest-activity cycle. When the circadian
rhythms of the body are synchronized with the zeitgebers,
the rhythm is optimally entrained. A type of insomnia
that is characterized mostly by complaints about initiating
sleep may be due to a misalignment of the circadian
rhythm in sleep-promoting physiology and the sleep
window the patient tries to adhere to, typically between
23:00 and 7:00 [12, 13].Homeostasis of sleep
In addition to the circadian regulation of sleep and
wake, a homeostatic component affects sleep propensity.
Whereas the circadian process is relatively independent
of prior sleep or wake, the homeostatic process on the
other hand is sensitive to the sleep-wake history [14].
The sleep homeostatic process increases sleep propen-
sity during wakefulness until sleep is initiated. Sleep pro-
pensity declines during sleep. The biological mechanisms
underlying sleep homeostasis are less well characterized
than the mechanisms underlying circadian regulation, but
likely involve astrocyte-dependent adenosine accumula-
tion [15, 16].
Some types of insomnia may involve altered homeo-
static regulation of sleep propensity [17].
Sleep-permissive and wake-promoting conditions
Although the regulation of sleep and wakefulness has
been well modeled by interacting circadian and homeo-
static processes in lab studies, additional sleep-permissive
and wake-promoting conditions have been largely over-
looked [18]. Most people sleep best lying in bed, with
the lights off and the curtains drawn, in a thermally
agreeable, safe and relatively quiet environment. These
parameters (posture, temperature, environmental light
and sound, fear) moderate the expression of sleep and
wake. Whether altered sensitivity to sleep-permissive and
wake-promoting conditions might be involved in the sleep
complaints of some types of insomnia remains virtually
unexplored [19–21].
Treatment of insomnia
Even though the underlying causes of insomnia are at
present insufficiently understood, one of the most com-
mon treatments provided by primary caregivers (mainly
general practitioners) is sedative or hypnotic drugs mostly
benzodiazepines or benzodiazepine receptor antagonists
[1]. Unfortunately, pharmacological treatments have a high
prevalence of adverse effects. Daytime drowsiness, risk of
abuse and addiction, and rebound insomnia on withdrawal
are a few examples of these side effects [22]. Pharmaco-
logical treatment is therefore not recommended [23].
In the past decades, two other interventions have been
developed. The first intervention is cognitive behavioral
therapy for insomnia (CBT-I). It has similar or even bet-
ter and more prolonged outcomes than pharmacological
treatment, and lacks the negative side effects [24]. A
second, less evolved, but promising type of intervention
is chronobiological treatment (CT). Chronobiological
treatments aim to enhance regular and appropriately
timed input to the circadian timing system to support its
role in sleep regulation, by use of bright light, body
warming or physical activity (for example, [21, 25, 26],
for a review see [27]). These manipulations may become
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related changes in the functional neuroanatomy of the
biological clock of the brain [28].
Cognitive behavioral therapy
Cognitive behavioral therapy for insomnia (CBT-I) is a
combination of cognitive and behavioral treatments.
CBT-I usually includes stimulus control (that is, associ-
ation of bed with sleeping), sleep restriction (that is,
restrict an individual’s time in bed to average sleep time),
relaxation training, cognitive therapy (that is, diminish
misconceptions about sleep) and sleep hygiene (for ex-
ample, general guidelines about behavioral and environ-
mental factors that influence sleep) [29]. CBT-I has been
shown to be effective in numerous randomized clinical
trials [24, 29–34]. A problem facing implementation on
a large scale is the lack of skilled therapists.
Chronobiological treatment
Three chronobiological manipulations have been applied
successfully and will be discussed below.
Bright Light (BL)
Bright light, including natural daylight, entrains the cir-
cadian rhythm [35]. Retinal ganglion cells projecting to
the SCN through the retinohypothalamic tract (RHT)
inform the circadian timing system about the intensity
of light exposure. The SCN uses this information to
entrain its intrinsic rhythmic activity to the 24-h light–
dark cycle [10]. Studies in humans show that phase
shifts can be imposed by manipulation of the light–dark
cycle [35, 36]. A phase advance can be induced by means
of bright light given in the morning, especially closely
after the body core temperature minimum; a phase delay
can be induced with light applied in the interval from
late afternoon to just prior to the body core temperature
maximum [35, 37, 38]. The effect of light on sleep may
not be limited to changing the sleep phase, as suggested
by studies that found enhanced sleep quality in the
absence of clear rhythm shifts [25, 39].
Body and skin warming (BW)
Core body temperature shows a clear 24-h rhythm. In
normal sleepers with a sleep period between 23:00 and
7:00, the temperature peaks between 18:00 and 20:00 h
and has its minimum between 4:00 and 5:00 h [11].
Apparently, the connection between sleep or vigilance
and core body temperature is strong. We sleep when
core body temperature is low and are awake when it is
high [18]. In contrast, skin temperature is increased
during the sleep period because of increased skin blood
flow in response to a supine posture [40]. Increased skin
blood flow promotes heat loss, resulting in a lower core
body temperature. Romeijn et al. [18] reviewed the effectof manipulation of skin temperature on vigilance, and
they explain in more detail the underlying processes.
Several studies that applied water-perfused thermo suits
to increase skin temperature slightly within the thermo-
neutral zone showed that this manipulation enhances
sleep propensity [18]. This effect has not only been dem-
onstrated in healthy adults, but also in people with in-
somnia [20, 21]. A more practical and home-applicable
version of this temperature manipulation is to make
use of the body’s thermoregulatory mechanisms and
warm the body prior to sleep by mild physical activity
or taking a hot bath [41]. About two hours later, core
body temperature has returned to baseline, while skin
temperature is still somewhat elevated. This pre-sleep
body warming approach has been used with success
in insomnia [42].Physical Activity (PA)
As diurnal mammals, humans are active during the day
and sleep at night. The rest-activity profile of people with
a very inactive lifestyle, for example sedentary elderly,
shows a small 24-h amplitude. Several studies evaluated
the effect of enhancing physical activity or exercising on
this amplitude and on sleep [26, 43–51]. Two possible
mechanisms have been proposed to be involved in the
effect of enhanced physical activity on sleep. The thermo-
regulatory hypothesis proposes that exercise exerts an
effect on sleep through initially increasing core body
temperature. This subsequently triggers heat loss to de-
crease the temperature, which is conducive to sleep. The
body restoration hypothesis proposes that exercise de-
pletes energy levels and promotes sleep because it in-
creases the need to activate restorative mechanisms. In
2000, Driver & Taylor reviewed the studies done up until
that year [46]. Unfortunately, most studies use good
sleepers. Their conclusion was that exercise of moderate
intensity and focusing on endurance rather than peak in-
tensity, was most beneficial for perceived sleep quality.
Tanaka et al. [51] showed that exercise is most effective
around 17:00 h, supporting the thermoregulatory hypoth-
esis. Benloucif et al. [43] however found equal effects of
morning and evening exercise on subjective sleep quality.
More recently, Passos et al. [50] summarized studies
using exercise in primary insomnia. This review demon-
strated improvement in sleep quality. Additionally, they
discuss possible explanations for the acute and chronic
effects of physical activity on primary insomnia [50].Optimizing treatment and accessibility
Whereas the combination of CT and CBT-I may be
more effective than their use in isolation, and has suc-
cessfully been applied in only one study [30, 52], no
prior study addressed the relative contribution of the
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to compare effectiveness of different combinations of
therapies; one of the aims of the present study.
A problem facing implementation of CBT-I is the short-
age of skilled therapists. Internet-based CBT-I may alle-
viate this problem [53]. Internet-based therapy is highly
self-guided, structured and personalized. Knowledge-based
technology renders a personalized concept consult, which
can be adjusted by therapist for situations that cannot be
pre-programmed. This saves a lot of time for a therapist
and subsequently may help to solve the discrepancy
between care needed and care available [33, 34], thus
allowing for large-scale implementation.
Another opportunity for the optimization of treatment
is based on the idea that the people suffering from insom-
nia most likely represent a heterogeneous mix of subtypes,
with different underlying causes and expected treatment
response. These subtypes may not only be distinguished
by type of sleep problems. Other factors such as personal-
ity traits, medical complaints and medical history, the
ability to perceive comfort [21, 54–56] may represent vari-
ables that differ between the proposed subtypes as well.
Our research group commenced a large-scale study using
web-based assessment of questionnaires to collect data
on these variables (the Netherlands Sleep Registry, NSR,
www.sleepregistry.org). The use of latent class analysis on
these data will allow for the data-driven detection of
multivariate subtypes, calculation of subtype probability
for participants according to this data-driven subtype
nosology, and evaluation of differential treatment re-
sponses, depending on the subtype probability.
The present study aims to evaluate the possibility to
optimize insomnia treatment along the principles of per-
sonalized and stratified medicine, by making the first
step towards the development of a protocol for individu-
alized optimal treatment for specific subtypes of insom-
nia, which each may show different responsiveness to
CBT-I and the different CT manipulations.Objectives
The objectives of this study are as follows:
1. To evaluate the relative effectiveness of internet-based
CBT-I, three different types of CT (light, temperature and
physical activity), and the combined application of CBT-I
and each of the CT’s, as compared to placebo treatment,
on [1] subjective sleep efficiency (primary outcome), [2]
subjective daytime functioning, [3] actigraphic sleep esti-
mates, and [4] cost effectiveness.
2. To evaluate whether insomnia subtype moderates
the effectiveness of the individual and the combined
treatments.
3. To evaluate whether the effect of CBT-I is enhanced
by prior CT.Methods/Design
Trial design
The study is a double blind, randomized, placebo con-
trolled trial. Aiming at 160 participants who complete
the trial, with a dropout rate of 10 %, 180 participants will
be recruited, who will be randomly assigned to one of
eight limbs in a repeated measures design with two fac-
tors (CBT-I and CT), of respectively 2 levels (active CBT-
I treatment versus waitlist monitoring) and 4 levels (light,
physical activity, body warming and placebo) (see Fig. 1).
Covariate-adaptive randomization aims at an equal repre-
sentation of insomnia subtypes within each treatment
limb. Assessment will be performed at baseline (week 0),
after a 4-week treatment period (week 5), and after a sec-
ond 4-week treatment/monitoring period (week 10).
Participants
Inclusion and exclusion criteria
Participants will be included that meet the criteria of an
insomnia disorder as defined in the DSM-V. Further-
more, participants have to be between 18 and 70 years
old. Because a meta-analysis [57] indicated that insomnia
is more prevalent in females (odds ratio (OR) = 1.41), we
aim for inclusion of 60 % females and 40 % males.
This study follows the Helsinki Declaration’s princi-
ples, meaning that all patients sign a written informed
consent stating that participation is voluntary and that
participation can be withdrawn at any time, without any
negative consequences concerning their current or fu-
ture treatment. Approval was obtained on 21 May 2013
from the medical ethical committee of the VU University
medical center in The Netherlands (Protocol 12/472).
The trial is registered at the Netherlands National Trial
Register (NTR4010) [58].
Participants are recruited through the Netherlands
Sleep Registry and (social) media. Interested candidates
fill out a screening questionnaire regarding health status
and insomnia diagnostic criteria (relevant items of Duke
Structured Interview for Sleep Disorders, DSISD) [59],
level of physical activity [60], light exposure (by asking
about habitual hours spent outside during daylight hours)
and bathing habits (frequency and duration of bathing/
showering). Participants will be excluded for the follow-
ing reasons:
1. their estimated baseline level and timing of activity,
bright light or body warming are already similar to
the CT interventions planned;
2. they report an eye disease incompatible with light
treatment (aphakia or retinopathy), or cardiovascular
or movement disorder incompatible with the exercise
treatment;
3. they report that they are currently diagnosed with a
psychiatric or neurological disorder;
Fig. 1 Flow chart of the trial design and outcome assessments. In the recruitment phase, participants fill out a questionnaire to assess their
eligibility to participate. This questionnaire includes the Duke Structured Interview for Sleep Disorder Diagnosis (30 min). During weeks 0, 5 and
10, participants fill out questionnaires and sleep diaries and will wear an actigraph for subjective and objective sleep estimates, respectively. The
diary is continued in all other weeks to support cognitive behavioral therapy (CBT). During weeks 1, 4, 6 and 9, participants will wear actigraphs
for objective measures of compliance to chronobiological treatment
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does not allow for alternative schedules, and their
sleeping problems may not be due solely to
insomnia; or
5. they use sleep medication regularly, unless they are
willing and able to restrict their usage to a
maximum use of twice a week, at least 1 month
prior to enrollment.
Randomization
Participants who meet the criteria and sign informed
consent will be randomly assigned to CBT-I or to the
waitlist and to one of the four CT conditions (including
one placebo). Simple randomization will be applied to
the first batch of 48 participants. During the staggered
entry of subsequent participants, covariate-adaptive ran-
domization [61] will be applied in order to maintain
balanced groups throughout the study. The covariates
are age, sex, use of non-sleep related medication and timeof year. Since some covariates are continuous rather than
categorical, randomization will be done following the
method proposed by Frane [62]. This method tempor-
arily assigns each new participant one by one to each
treatment group and obtains a P value of the test for
between-group differences for each of the covariates
for that assignment, using analysis of variance (ANOVA)
for continuous variables and a X2 test for categorical vari-
ables. This renders a P value for each of the four covari-
ates for each of the eight possible assignments. The lowest
of the four P values thus represents the least balanced
covariate in that assignment situation. These lowest, or
minimum, P values per assignment will then be used to
make the actual assignment to one of the treatment con-
ditions, where a participant will be assigned to the group
for which this minimum P value is highest, thus resulting
in a group assignment that keeps imbalance over groups
as small as possible. If group sizes become unbalanced
(that is, differing by more than five participants), the Frane
Dekker et al. Trials  (2015) 16:292 Page 6 of 12method will be applied only to the six smallest groups
instead of all eight. All randomization will be done using
R [63]. Randomization will be scripted, so actual group
assignment is automated.
Blinding and expectation assessment
A patient information letter explains the four CT manip-
ulations (including placebo CT) and CBT-I). All treat-
ments in the study are presented to the participants as
possibly effective. It is not possible to blind participants
to the different treatment conditions. Since all informa-
tion is given via email or through the postal service, there
will not be a blinding of instructors. However, CBT-I
counselors are instructed not to correspond about the
expected outcome of CT treatments, and participants
will be asked not to mention their CT condition in pos-
sible correspondence with the CBT-I counselor. When
participants, however, do reveal their condition, the CBT-I
counselor will be replaced. In order to secure blinded data
analysis, information regarding treatment conditions will
be coded. Only once data processing is finished and the
dataset is finalized, will the code will be broken. The
analyst (KD) will not have access to the key document.
Because all outcome assessments are either self-reported
through the internet or obtained from recording devices,
blinding of the assessors in not applicable. Judgments of
the participant on expected effectiveness will be assessed
at T0, T1 and T2 using a 7-point Likert-scale for each of
the treatments. After randomization, at T0, participants
will be asked about the expectation regarding their as-
signed CT and CBT-I. After treatment, at T1 and T2,
participants will be asked to what extent their sleep prob-
lems have changed compared to baseline and to what
extent they attribute this change to the treatment.
Study settings
All measurements and therapies are conducted at the
participants’ homes, using the Internet [64, 65]. Treat-
ment devices are sent to their homes. Participants are
informed on the types of treatment used in the study
and the objective of comparing them.
Interventions
Cognitive behavioral therapy for insomnia
All participants will receive internet-based, personalized
cognitive behavioral treatment for insomnia provided
through the Somnio website for 4 weeks. The Somnio
Internet therapy uses knowledge-based technology to
prepare a consult and support the therapist to apply the
protocol in a consistent and comprehensive way [66].
The personally assigned CBT-I therapist can adjust each
consult if needed. CBT-I will consist of four consults,
one every Monday morning. Every morning and evening,
participants fill out the Dutch online version of theConsensus Sleep Diary [67]. The first consult will be
based on the sleep diary data from the previous week, in
combination with the person’s beliefs and attitude towards
sleep, as assessed during week 0 by the Dysfunctional Be-
liefs and Attitudes towards Sleep (DBAS) questionnaire
[68]. Sleep diary data of the consecutive weeks will be
used to determine which cognitive and behavioral compo-
nents are emphasized during the treatment [66]. A more
detailed description of CBT-I has been provided earlier in
this article.
Chronobiological treatment
Physical Activity At enrolment, participants are asked
to fill out questionnaires to assess their health status as
well as the habitual level and timing of activity [60]. The
answers on an extended Baecke questionnaire will pro-
vide the necessary information to determine the specific
personalized implementation if they are randomized to
the physical activity condition. More specifically, in the
active treatment limb, the most intense physical activity
(PA) that participants report to habitually maintain for
at least half an hour (for example, (walking, running,
cycling) will be (re)scheduled to be performed daily for
half an hour preferably starting three hours before ideal
bedtime, and never ending closer than two hours prior
to ideal bedtime. The physical activity will thus at no
point exceed the participants usual duration and inten-
sity, but will be daily and set to a specific time of the day.
Body Warming For body warming (BW), participants
randomized to the temperature condition are instructed
to take a warm bath daily for half an hour, starting
3 hours before the ideal bedtime and never ending closer
than 2 hours prior to ideal bedtime. The physical activity
and temperature manipulation procedures will result in
elevated skin temperature at bedtime, which can enhance
sleep onset [18]. If the manipulations would be done
closer to bedtime, core body temperature would not have
returned to baseline at bedtime and possibly interfere with
sleep [18, 19].
Bright Light Participants randomized to the bright light
(BL) condition will receive a Philips goLITE BLU light de-
vice (HF3220/01, Philips Consumer Lifestyle, Drachten,
The Netherlands). They will be instructed to install the
light on a table facing a window to minimize glare by
reducing contrast between relatively small bright light
source and the background. The light will be set on the
side, within the range of vision, but not straight across
the participant. This will reduce strain on the eyes. They
will be asked to sit facing the light in close proximity for
half an hour at a fixed time each morning within an hour
after habitual wake-up time, for example during breakfast.
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testing the effect of morning bright light on seasonal
affective disorders (SAD), compare bright light with
negative air ionization [69–72]. These studies show that
morning High Density Negative Ionization (HDNI) is as
effective as morning bright light treatment. Negative air
ionization has been shown to positively affect cognitive
performance and depression [73]. The application has
not been evaluated for its possible effect on insomnia. In
one study on SAD, a deactivated ionizer (DI) was used
as placebo condition [74]. The ionizer was modified to
suggest normal functioning, as indicated by airflow, while
negative ion production had been deactivated. Treatment
outcome expectancy for the (deactivated) negative ionizer
was equal to that of BL. In the present study, participants
randomized to the placebo treatment will therefore re-
ceive a likewise deactivated ionizer (DI) device (Ionic Air
Purifier, XJ-2100, Shanghai Neo.Tec Electron Co., Ltd,
Shanghai, China). Participants will be instructed to install
the device on a table where they can sit in close proxim-
ity to it for half an hour each morning at their earliest
convenience after ideal wake-up time, for example during
breakfast. This placebo has been applied successfully in
several studies in the USA [69, 74], but not yet in the
Netherlands, making it unlikely to be recognized as a
placebo.
Assessments and outcomes
To assess subjective sleep parameters as well as daytime
complaints, participants will be keeping a diary in the
morning and evening for the entire 11-week protocol.
Sleep is assessed in the morning using the Dutch version
of the Consensus Sleep Diary [67]. Primary outcome,
sleep efficiency (the percentage of time slept during the
time in bed for sleep), is calculated from the sleep diary
variables as follows:
SE ¼ LightOn − LightOffð Þ − SOL − WASO − EMA
LightOn− LightOff
where SE is sleep efficiency; LightsOn is the moment
people indicated they stop trying to sleep, calculated
from their final wake up time and time they stayed in
bed to try to fall asleep again; LightsOff is the time
people turn off the lights and/or disengage from activ-
ities to go to sleep; SOL is sleep onset latency; WASO
is the time awake after sleep onset; and EMA is early
morning awakening, or the time people spend trying
to fall back asleep after final awakening.
Daytime functioning is assessed in the evening using
a dedicated questionnaire on all complaints listed in
the DSM-V and the International Classification of Sleep
Disorders, 2nd edition (ICSD-2). During week 0, partici-
pants will fill out the complete Duke Structured Interviewfor Sleep Disorders in order to have a complete overview
of sleep complaints and other medical and psychological
complaints they currently have or have had in the past.
During weeks 0, 5 and 10, participants will fill out a
comprehensive set of questionnaires:
1. Expectations or subjective outcome of the selected
treatments;
2. Health-related costs during the last 4 weeks
(Trimbos/iMTA questionnaire for Costs associated
with Psychiatric Illness: TiC-P) [75];
3. Functional health (Quality of Life Questionnaire,
Short Form 36, SF-36) [76];
4. Depression and anxiety (Hospital Anxiety and
Depression Scale, HADS) [77];
5. Mood (Positive Affect, Negative Affect Scale,
PANAS) [78];
6. Experience of pleasure and comfort (Temporal
Experience of Pleasure Scale, TEPS) [79];
7. Thoughts during resting state (Amsterdam Resting
State Questionnaire, ARSQ) [55]
8. Hyperarousal. Because this is considered a key
feature of insomnia, it is queried using four different
scales; the Arousal Predisposition Scale (APS) [80];
the Hyper Arousal Scale (HAS) [81]; the adult
ADHD Self-Report Scale (ASRS) [82]; and the
Pre-Sleep Arousal Scale (PSAS) [83];
9. Insomnia severity (Insomnia Severity Index,
ISI) [84];
10.Beliefs and attitudes regarding sleep (DBAS) [68];
11.Sleep effort (Glasgow Sleep Effort Scale, GSES) [85];
12.Sleep self-efficacy (Sleep Self-Efficacy Scale,
SSES) [86];
13.Sleep locus of control (SLOC) [87].
As shown in Fig. 1, ambulatory recordings will be per-
formed during the baseline week and the first week of
treatment (weeks 0 and 1), the last week of the CT treat-
ment period and the first week following completion
(weeks 4 and 5), and during weeks 9 and 10. During
these weeks, participants will continuously wear a wrist
actigraph to estimate sleep and light exposure (Philips
Actiwatch Spectrum, Philips Respironics, Murrysville, PA,
USA) and an accelerometer worn on the trunk to esti-
mate energy expenditure (Philips DirectLife, DL8700/01,
Philips, Eindhoven, The Netherlands).Compliance
CBT-I
Compliance with some aspects of CBT-I, for example
sleep restriction and stimulus control, can be monitored
using the sleep diary combined with the actigraphic sleep
estimates.
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Compliance with the chronobiological treatments will be
monitored by means of questions added to the sleep
diaries. Moreover, objective measures of compliance for
BL and PA can be derived from ambulatory monitoring
of physical activity and light exposure by the Actiwatch
Spectrum and DirectLife devices. Participants randomized
to BL are instructed to expose the Actiwatch Spectrum to
the light when sitting in front of the goLite BLU. Parti-
cipants assigned to BW receive a digital bath thermom-
eter (type: Lotus, Béaba, Oyonnax Cedex, France) and are
asked to register temperature of the bathing water to
monitor compliance with the body warming treatment.
Outcome measures
The primary outcome measure is the change from week 0
to week 5 in subjective sleep efficiency derived from the
sleep diary. Secondary subjective sleep estimates include
difficulties falling asleep, difficulties maintaining sleep,
early morning awakening and non-restorative sleep. A
secondary outcome regarding daytime consequences is
the average rating of evening diary ratings on eighteen
major daytime functioning complaints. Ancillary analyses
on persistence of treatment use the same variables ob-
tained in week 10.
Actigraphically estimated objective sleep parameters
(sleep efficiency, sleep onset latency, sleep duration, wake
after sleep onset, and the average durations of uninter-
rupted periods of sleep and wakefulness) are secondary
outcome measures meant to complement the subjective
evaluations. These are calculated from the ActiWatch
Spectrum recordings using the Respironics Actiware
software (version 5.71.0, Philips Respironics, Murrys-
ville, PA, USA). Given the variability in subjective [88]
and objective [89] sleep estimates, they will be assessed for
7 subsequent days at each assessment. Additional ques-
tionnaires, assessed in weeks 0, 5 and 10, will provide
secondary outcome measures (see the list above). Specific-
ally, the direct and indirect medical costs (TiC-P) will be
included.
Effect moderation by subtype score
Preliminary results of the Latent Class Analysis on com-
prehensive psychometric data of a large sample of parti-
cipants of the Netherlands Sleep Registry suggests the
existence of four different subtypes of insomnia, each
with about equal prevalence. From the extensive number
of questionnaires on traits these volunteers filled out, we
are presently selecting the minimal subset of questions
required to obtain good estimates of the a posteriori
probabilities of a participant to belong to each one of the
four classes. These items will be included in a Sleep
Subtype Survey that will be assessed in all participants of
the present RCT. The resulting four Insomnia SubtypeProbabilities (ISP) will be included in analyses aimed at
evaluating treatment effect moderation by each of the
four insomnia subtype probabilities.
Statistical analysis
Data reduction and reporting
The data of qualitative variables (for example, gender, type
of treatment, and insomnia subtype) will be presented as in-
cidence rates (number and percent). The data of continuous
variables (for example, age, measures derived from sleep
diaries, questionnaires and actigraphy) will be presented by
measures of central tendency (that is, mean and median)
and dispersion (that is, standard deviation and range).
Treatment effects and moderation estimates
Mixed effect models will be applied to estimate all time by
treatment effects, time by treatment interaction effects
and effect moderation by the individual’s insomnia sub-
type probabilities. For each outcome measure, all effects
will be estimated simultaneously in one single linear re-
gression equation. The primary outcome measure of sleep
efficiency will be illustrated below. The diary and actigra-
phy based outcome measures have a two-level hierarchical
data-structure: repeated measures of 14 diary inputs i
across T0 and T1 are nested within subjects j. The 14*160
= 2,240 data points can be used to estimate simultaneously
all effects ß using the following mixed effect model:
SEij ¼ ß0ij þ ß1Timeij þ ß2CBT‐Ij þ ß3BLj
þ ß4PAj þ ß5BWj þ ß6ISPj
þ ß7TimeijISPj þ ß8CBT‐IjTimeij
þ ß9CBT‐IISPj þ ß10CBT‐IjTimeijISP
þ ß11BLjTimeij þ ß12BLISPj
þ ß13BLjTimeijISPj þ ß14PAjTimeij
þ ß15PAISPj þ ß16PAjTimeijISPj
þ ß17BWjTimeij þ ß18BWISPj
þ ß19BWjTimeijISPj þ ß20CBT‐IjBLj
þ ß21CBT‐IjBLjTimeij þ ß22CBT‐IjBLjISPj þ ß23CBT‐ IjBLjTimeijISP
þ ß24CBT‐IjPAj þ ß25CBT‐IjPAjTimeij þ ß26CBT‐IjPAjISPj þ ß27CBT‐ IjPAjTimeijISPjþ ß28CBT‐IjBWj þ ß29CBT‐IjBWjTimeij
þß30CBT‐IjBWjISPj
þ ß31CBT‐ IjBWjTimeijISPj
In this regression equation, SE = sleep efficiency; ß0ij =
intercept; time denotes the post intervention (T1) versus
baseline (T0) assessment week; CBT = cognitive behavior
therapy assignment; BL = bright light assignment; PA =
physical activity assignment; BW = body warming assign-
ment; ISP = insomnia subtype probability; and ß1 to ß31
denote effect estimates. The effects and terms of interest
are shown in bold font. For example, line 2 shows in
bold font the overall treatment by time interaction effect
ß8 of CBT-I versus waitlist and the moderation of this
Dekker et al. Trials  (2015) 16:292 Page 9 of 12effect ß10 by one’s insomnia subtype probability. Lines 3
to 5 show the corresponding effect estimates for BL, PA
and BW interventions, and lines 6 to 8 the for their inter-
action with CBT-I. For clarity, the regression equation
shows only one of the four expected ISPs. Wald tests will
be used to evaluate the significance of the effect esti-
mates. Statistical significance is thresholded at p = 0.05.
The simultaneous estimation of all effects of interest in a
single regression model compensates for multiple com-
parisons. Mixed effect model analyses will be imple-
mented in MLwiN (version 2.02, Centre for Multilevel
Modelling, University of Bristol, Bristol, UK.) and (R: A
language and evironment for statistical computing, R
Foundation for Statistical Computing, Vienna, Austria.).
Power and sample size
Statistical power estimates
The statistical power of mixed effect regression models
with seven repeated measures (diaries) both before and
after intervention have been calculated according to the
equations given by Twisk, page 280 [90], similar to those
calculations made in a previous repeated measures RCT
that we published [91]. Statistical power calculations on
repeated measures require an estimate of the intraclass
correlation coefficient (ICC, that is, within-subject). We
estimated the ICC for the primary outcome measure of
subjective sleep efficiency from the 9-day sleep diaries
[67] that we recently assessed through the internet for 27
people suffering from insomnia according to an Insomnia
Severity Index ≥10 [92]. In agreement with the robust ob-
servation that night-by-night sleep variability is an intrin-
sic part of the insomnia symptomatology (reviewed in
[88]), we found only a moderate ICC of 0.27, supporting
the use of repeated assessment of the primary outcome
measure to increase statistical power of the design.
Given this moderate ICC of 0.27, seven pre-assessments
at T0, and seven post-assessments at T1, the 160 complet-
ing participants provide a power 1-beta of 0.80 to allow
for the detection, at a significance of alpha = 0.05, of even
small to medium main effects of CBT-I (minimal detec-
table difference d = 0.27 standard deviations), of each of
the three CTs (d = 0.31) and of their interaction with
CBT-I (d = 0.41). The minimally detectable difference in
the time by treatment interaction between any two types
of CT is small to medium as well (d = 0.38).
There is unfortunately no readily available method-
ology to estimate the minimally detectable moderation
effects of continuous variables (insomnia subtype prob-
abilities) on a time by treatment interaction effect on a
continuous outcome variable (sleep efficiency). In order
to obtain a conservative estimate of minimally detectable
moderation effects, we can dichotomize the continuous
insomnia subtype probability variable by means of a
median split, effectively generating two equal groups.The design then becomes one of three factors, each with
two levels: time (T1 versus T0), treatment group
(Treated versus Untreated on the specific intervention)
and insomnia subtype (high versus low probability) and
provides the ratio of available data in the subgroup or
interest relative to the other available data, to be used
once more in the equations given by Twisk, page 280
[90]. According to this conservative approach of map-
ping the continuous insomnia subtype probabilities onto
a dichotomous variable, the 160 completing participants
provide a power 1-beta of 0.80 to allow for the detection,
at a significance of alpha = 0.05: of a small to medium
moderation effects of insomnia subtype (1) on the time
by CBT-I treatment interaction (d = 0.31); (2) on the time
by each CT treatment interaction (d = 0.41); and (3) on
the difference in the time by treatment interaction be-
tween any two types of CT (d = 0.44). The smallest
detectable moderation effect of insomnia subtype on the
time by combined CBT-I and CT interaction is medium
sized (d = 0.55). We follow the convention on effect size
given by Cohen [93], who suggested consideration of an
effect size d of about 0.2 as “small” and an effect size of
about 0.5 as “medium.” With an estimated dropout of
10 %, we will recruit 180 volunteers. The expected 160
completers thus allow for the detection of small to
medium effect sizes.Discussion
The ultimate goal of this study is to develop a personal-
ized treatment protocol for insomnia disorder. Primary
caregivers could use this protocol to decide on the pri-
mary choice treatment for each individual patient. As-
sessment of insomnia subtype probabilities using the
Sleep Subtype Survey results in four ISPs, which can be
used to determine the expected treatment outcome of
each of four treatments, their combinations and their
simultaneous versus sequential application for the indi-
vidual patient.
Since all treatments used in this study are noninvasive,
easily applicable at home and require only the use of a
computer and Internet (CBT-I) and/or a readily available
therapy light (BL), the implementation of treatments is
straightforward, low-cost and scalable.
The current study addresses multiple opportunities to
optimize and personalize treatment of insomnia disorder.
First, no prior study has evaluated the relative effective-
ness of CBT-I, the three different forms of CT, and their
simultaneous or sequential combinations. Second, the
moderation of outcome by insomnia subtype probability
follows the principles of personalized and stratified medi-
cine. Treatment effects with subtype-specificity may come
to light that would have remained hidden in the unre-
cognized heterogeneity of the samples.
Dekker et al. Trials  (2015) 16:292 Page 10 of 12Trial status
Recruitment started in October 2013 and is ongoing. In
January 2014, the first participants enrolled. Currently,
60 participants have completed the protocol.
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